key: cord-0858760-hkfmk5nc
authors: Sen, Soma; Werner, Ann; Shekhar, Aditya
title: Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy
date: 2020-05-20
journal: Drugs Ther Perspect
DOI: 10.1007/s40267-020-00741-x
sha: 65f7413534814380495d22d5fdabf387faccb30d
doc_id: 858760
cord_uid: hkfmk5nc

nan

hydroxychloroquine did not. In terms of COVID-19 testing, 0.232% of all patients within the database system were tested, whereas 5.096% of patients with hydroxychloroquine prescriptions within the system were tested.

These results make a preliminary case for using hydroxychloroquine as a form of prophylactic treatment against COVID-19, considering the lower incidence of positive tests and no mortality among patients prescribed hydroxychloroquine. Furthermore, the fact that a greater percentage of patients with a hydroxychloroquine prescription were tested might reflect providers having higher indexes of suspicion of COVID-19 in these patients. This is interesting because our expectation is that an inherently immunocompromised population, such as one prescribed hydroxychloroquine, would be more likely to contract COVID-19. That being said, further study of hydroxychloroquine is warranted to ensure its efficacy as a means of prophylactically preventing the onset or progression of COVID-19. While these data are observational in a relatively small population and a clinical trial would be most helpful, we may lose valuable time and invaluable lives while waiting for trial results, considering the projected mortality due to COVID-19. We encourage other healthcare systems to examine their own databases to see if the trends we identified can be seen more broadly (Table 1) . 

Coronavirus may kill 100,000 to 240,000 in U.S. despite actions, officials say

World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Acknowledgements Data were provided by the Health Partners Insti-